

AWARD NUMBER: W81XWH-15-2-0031

TITLE: Novel Strategies to Improve Immunomodulation and Noninvasive
Clinical Monitoring in VCA

PRINCIPAL INVESTIGATOR: Bohdan Pomahac, MD

CONTRACTING ORGANIZATION: Brigham and Women's Hospital, Boston, MA

REPORT DATE: October 2021

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2021	2. REPORT TYPE Final	3. DATES COVERED 15Jul2015-14Jul2021
---------------------------------------	--------------------------------	--

4. TITLE AND SUBTITLE Novel Strategies to Improve Immunomodulation and Noninvasive Clinical Monitoring in VCA	5a. CONTRACT NUMBER W81XWH-15-2-0031
	5b. GRANT NUMBER MR140159
	5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S) Dr. Bohdan Pomahac	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER
	8. PERFORMING ORGANIZATION REPORT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital 75 Francis St Boston MA 02115	8. PERFORMING ORGANIZATION REPORT NUMBER
---	---

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSOR/MONITOR'S ACRONYM(S)
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
Safely minimizing the risks associated with vascularized composite allotransplantation (VCA) is crucial for functional restoration of wounded warriors. Our overarching goal is enabling functional and aesthetic restoration to patients with severe, unreconstructable vascularized composite tissue defects by safe VCA protocols with minimal side effects. Our specific aims are: (1) Establishing the efficacy of a low-dose IL-2 protocol at enabling minimization of immunosuppression to sirolimus monotherapy in recipients of VCA. (2) Exploring correlations between cellular and molecular immunoassays performed in specimens from VCA recipients (and their donors) with clinical observations of stability and rejection. In future trials, these assays can be developed into tools that prospectively predict rejection and tolerance in VCA, and (3) Implementing next-generation methods to supplement and potentially overcome limitations of established methods such as histology and ultrasound biomicroscopy (UBM). We are enrolling 5 subjects for VCA. <3 months after VCA, once recipient and allograft are stable, we will administer an IL-2 based protocol intended to enable minimization of immunosuppression to sirolimus monotherapy. Afterwards, immunosuppression will be weaned.

15. SUBJECT TERMS None listed.

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
Unclassified	Unclassified	Unclassified	Unclassified	7	

Contents

- 1. Introduction 4
- 2. Key Words: 5
- 3. Accomplishments..... 5
- 4. Impact..... 5
- 5. Changes/Problems 6
- 6. Products 6
- 7. Participant and other collaborating organizations 7
- 8. Special Reporting Requirements 7
- 9. Appendices 7

1. Introduction

Many individuals lose parts of their faces, their limbs or their abdomen in traumatic incidents such as active combat, burns, gunshot wounds, violent attacks, and motor vehicle accidents, amongst others. People with these types of traumatic injuries have decreased quality of life, and are often disabled. Although they may receive the best of the available conventional reconstruction therapies, they continue to suffer from chronic pain, psychological distress, social isolation, and limitations in their ability to perform daily activities such as bathing, dressing, ambulating, and eating without substantial help. “Vascularized composite allotransplantation”, or “VCA” for short, is a new promising therapy for these types of patients. Face transplants, hand transplants and abdominal wall transplants are examples of types of VCA.

The most significant disadvantage of VCA is that patients who receive this therapy must take immunosuppressive drugs for the rest of their lives in order to prevent their bodies from rejecting the transplant. Immunosuppressive drugs pose significant health risks. As VCA is not a life-saving therapy, the risks of immunosuppressive drugs are given much more consideration than in the case of, for example, a heart transplant. Therefore, many people who would benefit from VCA end up not receiving the therapy due to concerns about immunosuppression. We have developed a novel, safe treatment that may enable patients who receive VCA to drastically reduce or even completely eliminate immunosuppressive drugs in the months after transplantation. The objective of this study is to test this novel treatment in 5 patients who will receive VCA. At least 3 months after their VCA operations, our patients will receive our novel treatment which is based on low doses of “interleukin-2” or “IL-2” for short, over a period of 3-4 months. After receiving IL-2 treatment, we will try to minimize or possibly stop immunosuppressive drugs in our patients. If, however, we see signs of rejection, we give standard immune suppression back, which stops rejection successfully in the vast majority of VCA patients. We will follow the progress of our patients for 24 months thereafter. Using state of the art molecular, cellular and imaging technologies, we monitor the subjects’ immune status to identify patients who can safely minimize immune suppression and those who are likely to suffer rejection.

VCA will give many patients the opportunity to improve their quality of life and regain social participation and independence. Our study is carefully designed to thoroughly inform the patients about risks and benefits of participation, to minimize the incidence of complications, and if it is not possible to avoid them, have a safe treatment plan.

2. Key Words:

Vascularized composite allotransplantation, immune modulation, immune tolerance, IL-2

3. Accomplishments

Two patients were enrolled in this study. The first patient enrolled began recombinant IL-2 therapy in 10/2018. We continued to administer IL-2 in this patient until he was ultimately removed due to an adverse event in November 2019.

The second patient enrolled in this study (July 2019) was never started on IL-2 therapy due to several reasons. The patient's donor specific antibodies (DSA) were detected several months after transplantation and remain present. This is an exclusionary criterium. Additionally, due to pre-existing chronic renal insufficiency and worsening renal function, we transferred the patient to belatacept in order to minimize nephrotoxic effects of tacrolimus. This immunosuppression regimen is also not compatible with the original protocol.

We have continued providing post-operative care and continue to do so for both patients. We have also continued collecting biological samples from both patients as per Task 5 of the SOW.

Over the life of this project, we have:

- Reported to the FDA and maintained IND approval for use of IL-2 in this patient population for the time we had patients enrolled on the therapy. The IND approval has recently expired but with no patients on therapy currently, no further enrollment planned, and Dr. Pomahac's upcoming departure from the institution, we felt it was no longer a necessity.
- Made a great effort to recruit patients to this protocol but it is a difficult population to recruit and the pandemic further complicated this effort.
- Kept up with our monthly teleconference calls with the sponsor, as well as maintained up to date reporting requirements.

4. Impact

Active combat is inflicting multiple devastating injuries to unprotected body areas such as the face and limbs with alarming incidence, and resulting in limb amputation, facial disfigurement, and loss of abdominal wall. Conventional reconstructive surgery is limited in its ability to restore form and

function after these injuries. Disability with associated long-term medical care and disability benefit costs is common. Considering the high incidence and devastating consequences of these complex injuries to American Service members, there is a clear need to improve their treatment outcomes. Vascularized composite allotransplants provide a mean to functionally and cosmetically restore these tissues; however, at the cost of lifelong immunosuppression. If successful, these studies will facilitate induction of immunologic tolerance to the transplanted tissues thus improving the rate of return to duty, deployment and function of American service members and veterans recovering from combat-related limb loss, with associated improvements in quality of life, mental health, social participation and the American economy.

5. Changes/Problems

One of the most significant roadblocks in this project has been the slower subject recruitment than anticipated. This was due to low volume of referrals, no military referrals, and the recent limitations on patient interactions due to the COVID-19 pandemic. We screened six candidates, but all were found ineligible for transplant last year. Due to the slow recruitment rate, we were approved for a no-cost extension in July 2019. We had advertised our study in Plastic Surgery News periodicals as well as other professional magazines. We also reached out to our colleagues at MGH to team up in patient recruitment. Unfortunately, this effort was also unsuccessful.

Our patient who was receiving IL-2 developed hemolytic anemia in November 2019, after receiving a low, stable dose for over a year with no side effects. Hemolytic anemia is not a known side effect of IL-2, however, it could not be completely excluded as the cause. We therefore stopped IL-2 and switched the patient back to Prednisone. Since we were unable to determine the cause of the anemia, the patient was removed from the study.

6. Products

Nothing to report at this time.

Publications, Abstracts and Presentations

Oral Presentation: Part of the data from the first patient was presented at Military Health System Research Symposium (MSHRS) Conference 2019, Kissimmee, Florida, Aug 19-22.

Publication: Eskandari SK, Sulkaj I, Melo MB, Li N, Allos H, Alhaddad JB, Kollar B, Borges TJ, Eskandari AS, Zinter MA, Cai S, Assaker JP, Choi JY, Al Dulaijan BS, Mansouri A, Haik Y, Tannous BA, van Son WJ, Leuvenink HGD, Pomahac B, Riella LV, Tang L, Seelen MA, Irvine DJ, Azzi JR. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Sci Transl Med. 2020 Nov 11;12(569): eaaw4744. PMID: 33177180 (copy or publication attached)

Inventions, Patents and Licenses

Nothing to report at this time.

Reportable Outcomes

Nothing to report at this time.

Other Achievements

Nothing to report at this time.

7. Participant and other collaborating organizations

Dr. Riella left our organization in 2020 for Massachusetts General Hospital and his role has been replaced by Dr. Jamil Azzi, who has taken over his lab and all associated tasks for this project.

8. Special Reporting Requirements

None.

9. Appendices

Quad Chart

Copy of above mentioned publication